IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 14.690-14.940 for the period, compared to the consensus EPS estimate of 14.640. The company issued revenue guidance of $4.7 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX traded down $3.13 during trading hours on Wednesday, reaching $584.96. 206,389 shares of the stock traded hands, compared to its average volume of 583,421. The company has a market capitalization of $46.14 billion, a P/E ratio of 43.08, a price-to-earnings-growth ratio of 3.11 and a beta of 1.54. IDEXX Laboratories has a 52-week low of $518.55 and a 52-week high of $769.98. The company’s 50-day simple moving average is $558.15 and its two-hundred day simple moving average is $587.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts forecast that IDEXX Laboratories will post 14.68 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on IDEXX Laboratories
Key IDEXX Laboratories News
Here are the key news stories impacting IDEXX Laboratories this week:
- Positive Sentiment: Quarterly results exceeded expectations. IDEXX reported second-quarter EPS of $4.27, above the roughly $3.94-$3.95 analyst consensus, while revenue reached $1.217 billion versus expectations of approximately $1.20 billion. Revenue increased about 10% year over year, or 9% organically. IDEXX Laboratories Announces Second Quarter Results
- Positive Sentiment: Growth was broad-based. Companion Animal Group revenue rose 9%, Water revenue increased 15% as reported, and Livestock, Poultry and Dairy revenue grew 11%. Analysts also highlighted margin expansion and ongoing adoption of IDEXX’s diagnostic products as growth drivers. IDXX Q2 Earnings and Revenues Beat, 2026 EPS View Up
- Positive Sentiment: Fiscal 2026 guidance was raised. IDEXX provided EPS guidance of $14.69-$14.94, above the $14.64 consensus estimate. Revenue guidance was set at approximately $4.7 billion, in line with expectations, reinforcing confidence in earnings growth. IDEXX Laboratories Jumps on Strong Results and Raised Guidance
- Neutral Sentiment: Valuation remains elevated. Despite the strong report, IDEXX trades at a premium earnings multiple, which could limit further gains or increase sensitivity to any slowdown in veterinary demand or future guidance.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $26,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories during the second quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in IDEXX Laboratories during the third quarter valued at approximately $36,000. Johnson Financial Group Inc. raised its position in IDEXX Laboratories by 1,475.0% in the third quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock worth $40,000 after acquiring an additional 59 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in IDEXX Laboratories in the fourth quarter worth approximately $54,000. 87.84% of the stock is owned by hedge funds and other institutional investors.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
- CoreWeave Powers Up: The Asia Infrastructure Grab
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
